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Background: Long-term treatment with nucleos(t)ide ana-
logues (NUCs) is highly effective but HBeAg seroconversion and
HBsAg loss are very rare and unsatisﬁed event in CHB patients
with high viral load and, the resistance mutation and high relapse
rates block beneﬁt from antiviral treatment as well. The aim of the
present study is to evaluate the efﬁcacy and safety of a new ther-
apeutic strategy initial combining Lamivudine(LAM) and Adefovir
dipivoxil(ADV) in patients with HBeAg-positive chronic hepatitis
B(CHB).
Methods & Materials: One hundred and Eighty-two
treatment-naive CHB patients with HBeAg-positive and
HBVDNA≥105copies/ml were included and randomly divided
into three treatment groups, LAM monotherapy, entecavir(ETV)
monotherapy, and LAM+ADV combination therapy. The
patients in LAM+ADV group were treated with combination
LAM(100mg/day) plus ADV(10mg/day). LAM and ETV group
received LAM(100mg/day) and ETV(0.5mg/day) alone respec-
tively. Serum levels of ALT, creatinine, HBsAg, HBeAg and HBV
viral load, together with genotypic resistence were analyzed at
0,12,24,48,104 weeks, respectively.
Results:Of the 182 patients, themajority(82.5%) had serum lev-
els of HBVDNA over 107copies/ml. Baseline characteristics as for
HBV viral load, HBsAg and HBeAg titer, median age, serum levels
of ALT and creatinine were comparable between three groups. No
signiﬁcant differences in the rates of HBVDNA undetectable(<1000
copies/ml), HBeAg seroconversion, and ALT normalization were
found between LAM+ADV and ETV group at 12,24,48 and 104
weeks(p >0.05). However, these parameters were signiﬁcant
higher in LAM+ADVandETVgroup than those of LAMmonotherapy
group, allwithpvalue less than0.05,0.01and0.001. Comparedwith
LAMmonotherapy,ADV+LAMandETVhadanhigher response rates
at weeks 12,24,48 and 104. HBV viral load dropped sharply dur-
ing the ﬁrst four weeks. In 46%,49%;79%,78%;and 95%,92% patients,
the level became undetectable from week 24,48 and 104, respec-
tively. HBVDNA breakthrough was detected in 1.67%(ETV) and
36.1%(LAM) of monotherapy and 11.5% of combination therapy
patients. The M204V/I mutation was detected in 1.67%,34.4% and
11.5% of each group, respectively. No elevated serum creatinine
were found in three groups through the therapy course.
Conclusion: Lower rates of resistance, lower serum HBVDNA
levels and higher rates of HBeAg seroconversion were seen in the
combination therapy after two years.
http://dx.doi.org/10.1016/j.ijid.2014.03.1085
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Background: Outbreaks of the adenovirus group of infections
are reported often inmany countries, especially among young peo-
ple who live in the same types of circumstances. Adenovirus types
3, 4, 7, and 21 have the potential to cause pneumonia. In contrast,
adenovirus type 11 may cause cystitis, but cases of pneumonia due
to adenovirus type 11 were thought to be very rare.
Methods & Materials: In Tokyo, Japan, from April to July 2009,
74 young patients who live in the same dormitory presented at one
municipal hospital with similar symptoms including fever, cough,
and sore throat. Of these, 15 patients were diagnosed with pneu-
monia. To determine the outbreak of the pneumonia, sputum and
blood samples were collected for culture. Adenovirus rapid anti-
gen tests and adenovirus blood antibody tests were also carried
out. One patient underwent a transbronchial lung biopsy. In addi-
tion, their demographic data and the clinical features and courses
of all 15 pneumonia cases were reviewed.
Results:The averagepatient agewas25.5±3.74 (standarddevi-
ation) years old. Streptococcus pneumoniaewas detected by sputum
culture in one sample, but nothing was detected in all other blood
samples. Adenovirus rapidantigen testswerepositive in2of 9 cases
(22.2%). Blood levels of adenovirus type 11 antibody titer were ele-
vated in 4 of 7 cases (57.1%). Histopathology showed smudge cell
formation, and the test of adenovirus type 11 polymerase chain
reactions was positive for lung tissue biopsy. All cases resolved
without speciﬁc treatments.
Conclusion:Wedetermined theoutbreakof apneumonia group
infection by adenovirus type 11. Although pneumonia by adenovi-
rus type 11 was thought to be very rare, an adenovirus antigen or
antibody check including adenovirus type 11 should perhaps be
carried out in cases of pneumonia group infection among young
people.
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